Table 1.
Patient characteristics (N = 114).
| Age at starting TG, y | 42 (26-57) |
| Sex | |
| Female | 70 (61) |
| Male | 44 (39) |
| Disease duration, y | 3 (1-8) |
| Inflammatory bowel disease subtype | |
| Ulcerative colitis | 51 (45) |
| Crohn’s disease | 60 (53) |
| IBD undetermined | 3 (3) |
| Montreal Classification (UC) | |
| E1: proctitis | 3 (6) |
| E2: left-sided colitis | 26 (51) |
| E3: extensive colitis | 22 (43) |
| Montreal Classification (CD) | |
| Age at diagnosis | |
| A1 (≤16 y) | 1 (2) |
| A2 (17-40 y) | 35 (58) |
| A3 (≥40 y) | 23 (38) |
| Missing | 1 (2) |
| Disease location | |
| L1: only terminal ileum | 21 (35) |
| L2: only colon | 20 (33) |
| L3: ileum and colon | 18 (30) |
| +L4: locations proximal of ileum | 1 (2) |
| +P: perianal disease | 6 (10) |
| Missing | 1 (2) |
| Behavior | |
| B1: nonstricturing, nonpenetrating | 49 (82) |
| B2: stricturing | 8 (13) |
| B3: penetrating | 2 (3) |
| Missing | 1 (2) |
| Previous bowel surgery | 6 (5) |
| Smoking status | |
| Current | 16 (14) |
| Former | 22 (19) |
| Never | 62 (54) |
| Missing | 14 (12) |
| Comedication at the start of TG | |
| Corticosteroids | 43 (38) |
| Corticosteroid enema | 10 (9) |
| Mesalazine enema | 4 (4) |
| Mesalazine suppository | 2 (2) |
| Mesalazine | 48 (42) |
| Budesonide | 33 (29) |
| Combination enema (mesalazine + corticosteroids) | 9 (8) |
| None | 11 (10) |
Values are median (interquartile range) or n (%).
Abbreviations: CD, Crohn’s disease; TG, thioguanine; UC, ulcerative colitis.